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Objective. To validate the empiric observation that pH has an important eﬀect on oxygenation in infants receiving iNO. Study
Design. Demographics, ventilator settings, arterial blood gases (ABG), and interventions for up to 96 hours of life were extracted
from the charts of 51 infants receiving iNO. Need for ECMO and survival to discharge were noted. Mean blood pressure (MBP)
and mean airway pressure (MAP) were recorded. The arterial/alveolar (a/A) ratio was used as the primary outcome. Analysis
was by simple linear regression and multiple linear regression analyses and Fisher’s exact test. pH responsiveness was arbitrarily
deﬁned as a correlation coeﬃcient (CC) of >0.40 with P<0.05. Results. Mean gestational age was 38.8 weeks and mean birth
weight was 3300g. All patients had clinical diagnosis of PPHN. Clear responsiveness to pH was found in 31/51 infants. MAP and
MBP did not correlate with a/A ratio. Three responders had a critical pH > 7.55. Of 11 patients requiring ECMO, only 3 exhibited
responsiveness at any time in their course. Three responders required ECMO. Conclusion. This small study suggests that failure or
inability to optimize pH may account for observed unresponsiveness to iNO. Maintaining a pH > 7.5 using hyperventilation is not
recommended.
1.Introduction
Hypoxemic respiratory failure continues to be a signiﬁcant
source of morbidity and mortality for term and near-term
infants and is the most common reason for neonatal extra-
corporeal membrane oxygenation (ECMO) referral. Hypox-
emic respiratory failure is commonly associated with per-
sistent pulmonary hypertension of the newborn (PPHN),
a syndrome characterized by failure to achieve or maintain
the normal decrease in pulmonary vascular resistance (PVR)
that occurs after birth [1]. Increased PVR leads to pul-
monary hypertension, right ventricular dilatation, tricuspid
insuﬃciency, myocardial dysfunction, and extrapulmonary
right-to-left shunting, which leads to severe hypoxemia that
is often unresponsive to conventional therapy [2]. ECMO
remains a treatment of last resort, reserved for infants who
fail to respond to such therapies.
In the last decade and a half, multiple randomized cont-
rolled trials have shown that iNO improves oxygenation
and decreases the need for ECMO in term and near-term
infants with hypoxemic respiratory failure [3–8]. However,
up to 40% of infants treated with iNO in these pivotal
trials required ECMO. Response rate to iNO is inversely
related to the severity of pulmonary disease and is facilitated
by optimizing lung aeration by employing interventions
suchasexogenoussurfactantandhigh-frequencyventilation.
Despitethesemeasures,asigniﬁcantproportionofinfantsdo
not respond to iNO.
In our NICU at Georgetown University Hospital, iNO
has been in routine use for infants with hypoxic respiratory
failure who do not improve with high-frequency ventilation,
oxygen, inotropic support, and surfactant (when appropri-
ate, as in cases of RDS in late preterm infants or meconium
aspiration syndrome) since the late 1990s. We have made
the empirical observation that infants receiving iNO are
more likely to respond if their arterial pH is within high
normal range of 7.40–7.45 than if it is in the low normal
or acidotic range (< 7.35). Infants who had initially failed to
respond to iNO often demonstrated responsiveness when we
subsequently achieved a higher arterial pH.2 Pulmonary Medicine
Though Heidersbach et al. demonstrated in an animal
model that a systemic arterial pH > 7.40 augmented iNO-
induced pulmonary vasodilation, extensive review of the
literature failed to reveal any clinical observation of this
phenomenon. The objective of this study was to explore the
relationship between arterial pH and oxygenation in near-
term infants with severe hypoxemic respiratory failure who
were being treated with iNO.
2. Study Design
AfterobtainingHIPAAwaiver,alltermandnear-terminfants
who received iNO treatment for PPHN in the Georgetown
University Hospital NICU during a 5-year period were
identiﬁed from our neonatal information system (NIS)
database. The medical records were obtained, and each was
assigned a sequential number not related to the medical
record number for organizational purposes.
Available records were reviewed, and the following infor-
mation was recorded by the principal investigator (AMB):
gestational age, birth weight, gender, ethnicity, maternal age,
age in hours at time of presentation, primary diagnosis,
echocardiographic evidence of PPHN (elevated right ven-
tricular pressures with or without right to left shunting),
inborn/outbornstatus,useofdopamine,dobutamine,epine-
phrine, or hydrocortisone, use of antibiotics, and outcome
(death, ECMO, or recovery without ECMO). The informa-
tion was recorded into a data collection form and was orga-
nized by the assigned number.
Additional data collected for each infant included a
baseline arterial blood gas (ABG), deﬁned as the ABG prior
to initiation of iNO; baseline ventilation mode and settings
just prior to initiation of iNO therapy; age in hours at
initiation of therapy; post-iNO ABG (ﬁrst gas after initiation
of therapy); all available ABG results for the ﬁrst 96 hours
on iNO (or until iNO was discontinued for recovery, ECMO
or death); mean blood pressure (MBP) at the time of the
blood gas determination; mean airway pressure (MAP) at
the time of blood gas determination; ventilation changes;
“pH interventions” (deﬁned as sodium bicarbonate, THAM,
or ﬂuid bolus); additional interventions such as surfactant
administration.
In our NICU, metabolic acidosis in infants with PPHN
is corrected with ﬂuid boluses and sodium bicarbonate.
Fluid boluses are also used to maintain blood pressure if
other signs of hypovolemia (tachycardia, poor perfusion)
are present. THAM is used only in cases of metabolic
acidosis with poor ventilation (increased PaCO2). It is not
our practice to use sodium bicarbonate or THAM to induce
alkalosis.Hydrocortisoneisgiveninourunitforhypotension
refractory to volume expansion and maximum dopamine
and dobutamine support. Hourly MAP and MBP are
available on all of our PPHN patients, and scheduled blood
gas determinations are usually taken on the hour. The MAP
and MBP closest to the time of all blood gas determinations
were recorded. Frequency of ABG measurements is based on
clinical status of the infant, ranging from hourly (or more
frequently) in the early, more critical period, to every two
to four hours once the infant has stabilized. Our practice
with respect to target PaCO2 has evolved over time, shifting
away from aggressive hyperventilation to more recently
maintainingPaCO2 levelswithinanormaltomildlyalkalotic
range (30–45torr). During the earlier period of the study,
there was some practice style variation leading to moderate
hyperventilation in some infants.
The a/A ratio [PaO2/(760–47) × (FiO2/100)-PCO2], rat-
her than PaO2, was used to assess oxygenation in order to
account for the eﬀect of changes in PaCO2 and FiO2.W e
elected not to use the oxygenation index (MAP × FiO2 ×
100/PaO2), because mean airway pressure does not correlate
well with oxygenation when the cause of hypoxemia is
extrapulmonary, rather than intrapulmonary shunting.
To protect privacy of patient information, the principal
investigator kept the assignment log in a password-protected
ﬁle. The study was approved by the Georgetown University
Institutional Review Board, which granted waiver of HIPAA
and informed consent requirements.
3.StatisticalMethods
First we performed univariate analyses using simple linear
regression to determine the correlation coeﬃcient (CC) for
pH, MBP, MAP, and time since start of iNO versus a/A ratio.
Responsiveness to pH in each infant was arbitrarily deﬁned
as a positive correlation coeﬃcient of >0.40 with a P value
of < 0.05. Because pH sensitivity wanes as vasoconstriction
subsides,analysiswaslimitedtotheperiodofresponsiveness,
if present. This period was determined by consensus of the
investigators using visual examination of the pH and PaO2
data. Multiple linear regression analysis was then performed
to determine possible independent eﬀect of each variable
(pH, MBP, MAP, and time) on responsiveness. Fisher’s exact
test was used to compare the need for ECMO in pH respon-
ders versus nonresponders. Each patient’s data plotted in a
pH versus PaO2 graph were visually examined to determine
the “critical pH” at which oxygenation responsiveness was
achieved. For patients with a clear inﬂection point to their
a/A ratio versus pH graph, the critical pH was determined by
the value of pH at the inﬂection point. Nineteen of thirty-
one pH-responsive infants had such an inﬂection point. In
the remaining infants who had a fairly linear relationship
between pH and a/A ratio, we arbitrarily chose the pH at
which PaO2 exceeded 100mmHg with FiO2 of 1.0 as the
“critical pH.”
4. Results
Fifty-nine potential study patients were identiﬁed. Two
records could not be located and of the remaining ﬁfty-seven
infants two were excluded due to prematurity, one because
of unavailability of arterial blood gases (no arterial line), one
due to congenital heart disease recognized only after being
placed on iNO and two because of incomplete data. In total,
ﬁfty-one records were retained for analysis.
Table 1 shows the demographics of the study patients.
There was no statistical diﬀerence in mean birth weight,
mean gestational age, primary diagnosis, or mean age at
iNO initiation between pH responders and non-responders.Pulmonary Medicine 3
Table 1: Demographic data for study patients according to pH responsive status.
Responders (n = 31); (60.7%) Non-responders (n = 20) (39.2%)
Mean birth weight 3343gm (2040–5178) 3257gm (2670–4200)
Mean gestational age 39wk (36.14–41.86) 38.45wk (35.14–41.71)
Males:females 17:12 16:6
Primary diagnosis
Meconium aspiration syndrome (MAS) 12 (39%) 13 (65%)
Congenital diaphragmatic hernia (CDH) 1 (3%) 2 (10%)
Pneumonia 4 (13%) 1 (5%)
Asphyxia 1 (3%) 2 (10%)
Blood aspiration 2 (6%) 0
Sepsis 5 (16%) 4 (20%)
Cardiomyopathy 1 (3%) 0
Respiratory distress syndrome (RDS) 3 (10%) 0
Mean age at iNO initiation 23.2hours 25.1hours
ECMO 3 (10%) 8 (40%)
No ECMO 28 (90%) 12 (60%)
Survival to discharge 31 (100%) 19 (95%)
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Figure1:Linearresponseofa/AratiotoarterialpHinanindividual
patient. Correlation coeﬃcient = 0.836, P<0.01.
As expected, there were more males than females in each
group, with a higher proportion of males falling into the “pH
nonresponsive” group.
Ninety-two percent of the infants were outborn. All
infants received antibiotics for treatment of possible sepsis
and dobutamine and dopamine (at maximum dosage of
20mck/kg/min) for blood pressure support. Thirty-two
of ﬁfty-one patients (63%) received hydrocortisone for
blood pressure support. Forty-seven of 51 infants (92%)
had elevated right cardiac pressures, suggesting pulmonary
hypertension. Seventy-three percent of the infants were
on high-frequency ventilation (HFV) at the initiation of
iNO, including sixty-nine percent of pH responders and
seventy-seven percent of nonresponders. One infant in each
groupwastreatedwithhigh-frequencyoscillatoryventilation
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Figure 2: An extreme example of a threshold response of a/A ratio
to arterial pH in an individual patient. Correlation coeﬃcient =
0.614, P<0.01. In this instance simple linear regression is not the
optimal statistical approach, as the relationship is clearly not linear.
(HFOV), the remaining thirty-ﬁve with high-frequency jet
ventilation (HFJV). All infants were started at a dosage of
20ppm iNO.
Thirty-one of ﬁfty-one infants were classiﬁed as pH
responders (61%) using the criteria listed in the statistical
methods section. Among responders, the critical pH ranged
from7.3to7.6withtwentyofthirty-oneinfantsdemonstrat-
ing critical pH of < 7.5. Only three infants had a critical pH
> 7.55.
As described in the Methods section, two patterns of pH
responsiveness for individual patients were observed: a fairly
linear relationship between pH and a/A ratio (Figure 1),
or a clear threshold-response of a/A to pH (Figure 2). The
eﬀect of pH on oxygenation waned over time as oxygenation
improved and the infant transitioned from predominantly4 Pulmonary Medicine
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Figure 3: Need for ECMO in responders versus nonresponders.
PPHN pathophysiology to a phase where parenchymal lung
disease predominates. The data presented in the Figures and
subsequent analyses represent the period of responsiveness
for those patients who exhibited the pH response.
Three infants who were pH responders early in their
course ultimately required ECMO. All three patients had
critical arterial pH > 7.5. Eight of the 20 (40%) “pH
non-responsive” infants required ECMO: three infants were
cannulated within 12 hours of life, one within 3 hours of
arriving at our center. Two of the patients classiﬁed as pH
non-responsive never achieved a pH ≥ 7.3, and one had a
bestpHof7.37.Fouroftheremainingﬁveinfantsdidattaina
pH ≥ 7.5, but without a sustained response in PaO2. Patients
whowerepHresponsiveweremuchlesslikelytoneedECMO
(10% versus 40%, P = 0.012, OR 0.16, 95% CI 0.027–0.84,
Figure 3). Only one study patient died. This infant was a
nonresponder and died before ECMO could be instituted
with a diagnosis of sepsis and pneumothorax.
By multiple logistic regression, pH but not mean blood
pressure was independently correlated with oxygenation.
In pH-responsive infants, mean blood pressure showed
no correlation with a/A ratio, while there was a weak
(nonsigniﬁcant) correlation between MBP and oxygenation
in pH non-responsive infants. Contrary to the usual posi-
tive correlation of MAP and oxygenation, MAP showed a
negative correlation with a/A ratio suggesting that poor oxy-
genation prompted increases in MAP, to which the infants
did not respond, because the etiology of the hypoxemia
was extrapulmonary, rather than intrapulmonary shunting.
Therewasnosigniﬁcantassociationbetweenanyoftheother
therapeutic interventions we examined and a/A ratio.
Because the critical pH varied greatly between patients,
the correlation was much higher for individual patients
(range 0.427 to 0.938, P<0.0001 to 0.04) than for all pH
responders as a group, although the group as a whole did
show a highly statistically signiﬁcant response to pH (CC =
0.302, P<0.0001).
5. Discussion
Achieving optimal aeration of the lungs, adequate sedation,
and blood pressure support are recognized as important fac-
torsinfacilitatingresponsivenesstoiNO.Theroleofalkalosis
has long been appreciated in the treatment of PPHN, and,
despite only limited evidence of short-term safety (with no
long-term follow-up) [9], it was for many years the mainstay
of treatment for this condition. A 1999 study by Heidersbach
and colleagues demonstrated dose-dependent pulmonary
vasodilationinalambmodelinresponsetooxygen,alkalosis,
and iNO. They proceeded to demonstrate that when the
therapies were used in combination, a systemic arterial pH
> 7.40 augmented iNO-induced pulmonary vasodilation
[10]. The present review was undertaken to examine the
validity of the empiric observation that many babies with
PPHNcontinuetoexhibitpH-responsivenesswhenreceiving
treatment with iNO. Using the previously described criteria
(positive correlation coeﬃcient of > 0.40 with a P value of
< 0.05, for a/A ratio versus pH), pH responsiveness was
found in 61% of the infants studied—however, some degree
of responsiveness was seen in many other infants who did
not meet the strict criteria for pH response. There were
ﬁve infants who always had a pH > 7.40 and maintained
good oxygenation once started on iNO. By our deﬁnition,
they were classiﬁed as non-responders, though their pH
sensitivity was not, in fact tested. Responsiveness to pH,
when present, typically manifested itself within the ﬁrst few
hours of iNO therapy.
As expected, those who were pH responsive were much
less likely to need ECMO. The rate of 40% need for ECMO
in non-responders is consistent with the pivotal iNO trials,
while the rate of 10% in responders is much lower. The
overall use of ECMO in our institution for infants receiving
iNO during this period was 24%.
We suspect that three of the infants cannulated for
ECMO in the non-responsive group may not have achieved
as u ﬃcient pH to determine if they may have been pH
responsive. They were cannulated within 12hours of life—
one within three hours of arrival to our institution. It is
unknown whether better pH simply could not be achieved
or whether higher pH was not attempted in these patients.
Induced systemic hypertension is often used to overcome
the high pulmonary pressures encountered in PPHN. While
westill strive to maintain adequateblood pressuresin infants
with PPHN, we found that attaining higher than normal
blood pressure was not signiﬁcantly correlated with response
to therapy in our pH-responsive infants. It was, however,
weakly correlated with response to therapy in pH non-
responsive infants, suggesting that the MBP eﬀect may be
simply masked by the more dramatic pH eﬀect.
Most infants with pH-responsiveness had a critical pH
in the range of 7.4–7.5. All three pH responsive infants
who eventually required ECMO had a “critical pH” greater
than 7.5. Indeed, in some instances, it was a conscious
decisiontoforgosuchdegreeofalkalosisand,whenadequate
oxygenation could not be maintained with more normal
pH, ECMO therapy was initiated. Our data suggest that the
likelihood of sustained beneﬁt is low if iNO responsivenessPulmonary Medicine 5
cannot be achieved at modest degrees of alkalosis. It has
been observed that production of hypocapnia in infants with
PPHN counteracts hypoxic vasoconstriction, thereby allow-
ing increased blood ﬂow [11]. This eﬀect appears to be more
related to the change in arterial pH than hypocapnia [11],
and therefore, overventilating infants for this purpose is not
recommended in light of potential long-term lung damage
from such an action. Because of this and the possibility
of serious adverse eﬀects of hypocapnia on cerebral blood
ﬂow [12, 13], we strongly believe that infants should not be
maintained with pH > 7.5 or PaCO2 < 30. In our institution,
any infant that continues to require pH greater than 7.5 to
achieve iNO responsiveness is now considered a candidate
for ECMO, even in the absence of other indications such as
hemodynamic instability, and so forth.
In analyzing our data, we recognized that pH and
PaO2 values much higher than desired occurred with some
frequency. These values were typically seen in infants on
high-frequency ventilation where even a modest increase
in tidal volume can result in a large increase in minute
ventilation and thus hypocapnia, because of the geometric
relationship between tidal volume and minute ventilation
(minute ventilation is proportional to tidal volume [2]).Fur-
thermore, though right-to-left shunting aﬀects oxygenation
more dramatically than CO2 removal, decreased pulmonary
b l o o dﬂ o ww i l lr e d u c eC O 2 removal proportionally. When a
“critical pH” is reached and the shunt is reversed resulting
in a substantial increase in pulmonary blood ﬂow, the pCO2
will often drop more than desired. For this reason, we
now monitor PCO2 transcutaneously in all infants with
PPHN, especially when on HFV. Excessively high PaO2 also
commonly occurs in these infants when the extrapulmonary
right-to-left shunt is reversed, and may remain well above
target values for some time as the FiO2 is weaned, sometimes
too cautiously. Thus, it is clear that the eﬀects of inter-
ventions aimed at optimizing ventilation must be carefully
monitored in order to avoid excessive degrees of alkalosis,
hypocapnia, and hyperoxia.
This study is limited by its retrospective nature, lack of
long-term followup, and relatively small numbers. Some of
the infants did not experience a wide enough range of pH
to determine the eﬀect of pH on their response to iNO.
The relationship we demonstrated is merely an association
and may not be causative, though there clearly is a plausible
pathophysiologic mechanism for the observed relationship,
and similar relationship was observed in the laboratory [14].
It could be argued that the observed association between
higher pH and improved oxygenation reﬂects improved
ventilation-perfusion ratio as a result of the selective vasodi-
latation of the well-ventilated portions of the lung. However,
there were many instances where, after an initial improve-
ment in oxygenation at a higher pH, the ventilator settings
were reduced and with rising PaCO2 and falling pH, there
was a reversion to hypoxemia, even while the iNO therapy
continued.Thisleadsustobelievethattheeﬀectgoesbeyond
thedirectinﬂuenceofiNOontheeﬀectivenessofventilation.
Although sodium bicarbonate infusions were occasionally
used to correct metabolic acidosis, the major contributor to
pH changes was reduction in PCO2. It is possible, therefore,
that some of the observed “pH responsiveness” may also be
due to improved delivery of the iNO as a result of increased
ventilator support and improved lung aeration.
As in all retrospective analyses, certain arguably arbitrary
decisions and judgments had to be made. It is well known
by most clinicians that infants with PPHN eventually lose
their responsiveness to alkalosis. This is not an abrupt
change, but rather a gradual transition from a phase during
which pulmonary hypertension is the primary cause of
the oxygenation defect to a “transitional phase” during
which ventilator-induced lung injury plays an increasingly
prominent role and pulmonary hypertension subsides [15].
This phenomenon was clearly seen in many of our infants
who early in their course had a well-deﬁned critical pH,
but over time this responsiveness disappeared. We had to
make the most objective decision we could as to when this
transition occurred and when to truncate the data analysis.
While we recognize this to be a potential limitation of this
review, we do not believe this is a serious problem, because,
while a ﬂawed judgment in this process could change a
pH responsive patient into a non-responder, the opposite
is not true; if there were not a ﬁnite initial period of pH
responsiveness with a suﬃcient number of data-points to
reach statistical signiﬁcance, eliminating later values would
not create a signiﬁcant correlation coeﬃcient. Therefore, the
risk, if any, is to underestimate the number of responders, an
issue already addressed elsewhere. Our deﬁnition of “critical
pH” in infants with a relatively linear relationship as the pH
at which PaO2 was > 100 was quite arbitrary. The purpose
wastodeﬁnealevelatwhichmost,ifnotall,clinicianswould
agree that oxygenation is more than adequate. Despite this
rather “conservative” deﬁnition, the “critical pH” was below
7.5 in a large majority of the infants, supporting the concept
thatmarkedalkalosisisnotonlyundesirable[14],butusually
also unnecessary.
Despite the above limitations, based on our data, we
propose that carefully performed optimization of pH in the
high normal range should be considered as a potentially
useful adjunct to iNO therapy and should be added to the
list of measures that might be taken to optimize an infant’s
chance to achieve an optimal response to iNO. We do not
have developmental follow-up data to inform whether the
mild to moderate alkalosis that helped to avoid the need
for ECMO was associated with adverse neurodevelopmental
outcomes. Therefore, it must be recognized that a deﬁnitive
assessment of the risks and beneﬁts of mild alkalosis is not
possible without an adequately powered prospective ran-
domized trial with long-term followup aimed at measuring
both neurodevelopmental and pulmonary outcomes.
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